COPENHAGEN, Oct 10 (Reuters) – Exelixis’ drug
Cabometyx beat Pfizer’s Sutent in a clinical study in
metastatic kidney cancer, suggesting it has the potential to
become a first-line treatment,…
The post Exelixis and Pfizer drugs face off in kidney cancer appeared first on NASDAQ.